Pirfenidone controlled-release - Overseas Pharmaceuticals
Alternative Names: Pirfenidone modified release - Overseas PharmaceuticalsLatest Information Update: 19 Sep 2024
At a glance
- Originator Overseas Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Heart failure therapies; Pyridones; Small molecules
- Mechanism of Action Collagen inhibitors; Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 26 Aug 2024 Preclinical trials in Idiopathic pulmonary fibrosis in China (PO), prior to August 2024
- 23 Aug 2024 Overseas Pharmaceuticals plans a phase I trial for Idiopathic pulmonary fibrosis (In volunteers) in China (PO, Tablet), in August 2024 (NCT06569381)
- 27 Apr 2024 Overseas Pharmaceuticals completes a phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in China (PO) (NCT06588517)